Stock Track | Artivion Plunges 28.66% in Pre-market as Multiple Analysts Slash Price Targets After Lowered Guidance

Stock Track

Yesterday

Artivion's stock experienced a severe pre-market plunge of 28.66% on Friday, extending significant losses from the previous trading session.

The sharp decline follows a wave of analyst price target cuts issued in response to the company's recent financial updates. Canaccord Genuity lowered its target to $36 from $48, Stifel reduced its target to $45 from $55, Citizens cut to $48 from $53, and Oppenheimer slashed its target to $38 from $50.

These downward revisions come after Artivion reported first-quarter earnings and concurrently lowered its full-year 2026 financial outlook. The company reduced its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast. Investor sentiment was further impacted by the announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105177965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105177965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105177965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105177965","market":"nz","top_or_hot":-1,"title":"Stock Track | Artivion Plunges 28.66% in Pre-market as Multiple Analysts Slash Price Targets After Lowered Guidance","media":"Stock Track","content":"<p>Artivion's stock experienced a severe pre-market plunge of 28.66% on Friday, extending significant losses from the previous trading session.</p><p>The sharp decline follows a wave of analyst price target cuts issued in response to the company's recent financial updates. Canaccord Genuity lowered its target to $36 from $48, Stifel reduced its target to $45 from $55, Citizens cut to $48 from $53, and Oppenheimer slashed its target to $38 from $50.</p><p>These downward revisions come after Artivion reported first-quarter earnings and concurrently lowered its full-year 2026 financial outlook. The company reduced its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast. Investor sentiment was further impacted by the announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Artivion Plunges 28.66% in Pre-market as Multiple Analysts Slash Price Targets After Lowered Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Artivion Plunges 28.66% in Pre-market as Multiple Analysts Slash Price Targets After Lowered Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Artivion's stock experienced a severe pre-market plunge of 28.66% on Friday, extending significant losses from the previous trading session.</p><p>The sharp decline follows a wave of analyst price target cuts issued in response to the company's recent financial updates. Canaccord Genuity lowered its target to $36 from $48, Stifel reduced its target to $45 from $55, Citizens cut to $48 from $53, and Oppenheimer slashed its target to $38 from $50.</p><p>These downward revisions come after Artivion reported first-quarter earnings and concurrently lowered its full-year 2026 financial outlook. The company reduced its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast. Investor sentiment was further impacted by the announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AORT","symbol_name":"Artivion","start_time":0,"source_url":"","article_id":"1105177965","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105177965","pubTimestamp":1778246855,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Artivion's stock experienced a severe pre-market plunge of 28.66% on Friday, extending significant losses from the previous trading session.The sharp decline follows a wave of analyst price target...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AORT":"Artivion"},"translate_title":"个股追踪|Artivion盘前暴跌28.66%多位分析师下调指引后大幅削减目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1},"content_text":"Artivion's stock experienced a severe pre-market plunge of 28.66% on Friday, extending significant losses from the previous trading session.The sharp decline follows a wave of analyst price target cuts issued in response to the company's recent financial updates. Canaccord Genuity lowered its target to $36 from $48, Stifel reduced its target to $45 from $55, Citizens cut to $48 from $53, and Oppenheimer slashed its target to $38 from $50.These downward revisions come after Artivion reported first-quarter earnings and concurrently lowered its full-year 2026 financial outlook. The company reduced its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast. Investor sentiment was further impacted by the announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}